Findings from SWOG S1801, a randomized phase II study of adjuvant vs neoadjuvant therapy with pembrolizumab, were presented by Patel et al at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA6).
Question 1 of 5
Why was it hypothesized that neoadjuvant therapy with pembrolizumab could be more beneficial than adjuvant therapy?
